Translating groundbreaking science into tomorrow’s cures

Pioneering the future of genomic medicine

Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.

Explore our pipeline

Patient Stories

Read Elizabeth’s
inspiring story
of living with
Fabry disease

The Latest at Sangamo

News Release

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
News Release

Sangamo Therapeutics Announces Preliminary Phase 1/2 Proof-of-Concept SAR445136 Data Showing Tolerability and Sustained Effect in Sickle Cell Disease
News Release

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
News Release

Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
Perspective

Our CEO, Sandy Macrae, looks back at #genomicmedicine in 2021, acknowledging the challenges the industry faced & sharing why he believes successes can only be measured by the difference we make for patients. Read the article.
Careers

Sangamo is seeking top talent to join our mission as a Principal Research Associate/Scientist. This position is part of the Vector Production and Development Group, responsible for optimization of lentivirus production procedures and manufacturing lentivirus to support our research and preclinical programs. Click here to learn more about the open position: https://bit.ly/3CTwCmV #Biotech #WeAreHiring #BiotechJobs

Latest Publications & Presentations

All Publications

All Presentations

Our Pipeline

Phase 3

Hemophilia A

Giroctocogene Fitelparvovec

|

Gene therapy
Cell therapy
Genome engineering

Learn more about our clinical trials

Phase 1/2

Fabry Disease

Isaralgagene civaparvovec
Renal Transplant

TX200
Sickle Cell Disease*

SAR445136

|

Preclinical

Inflammatory Bowel Disease
Renal Transplant

(Allogeneic)
Multiple Sclerosis
Prion
Neurology

Undisclosed
Oncology

KITE-037

|
Oncology

Undisclosed

|
Neuro- developmental Disorders

|
ALS/FTD

|
Huntington’s Disease

TAK-686

|
a-Synuclein

ST-502

|
Tauopathies

ST-501

|
Neurology

DMI

|
Neurology

Undisclosed

|

*Transitioning to wholly owned program in June 2022

Translating groundbreaking science into tomorrow’s cures

Pioneering the future of genomic medicine

Read Elizabeth’s
inspiring story
of living with
Fabry disease

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

Sangamo Therapeutics Announces Preliminary Phase 1/2 Proof-of-Concept SAR445136 Data Showing Tolerability and Sustained Effect in Sickle Cell Disease

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference

Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo

Our CEO, Sandy Macrae, looks back at #genomicmedicine in 2021, acknowledging the challenges the industry faced & sharing why he believes successes can only be measured by the difference we make for patients. Read the article.

Anion-Exchange HPLC Assay for Separation and Quantification of Empty and Full Capsids in Multiple Adeno-Associated Virus Serotypes

ZFN-Mediated In Vivo Gene Editing in Hepatocytes Leads to Supraphysiologic α-Gal A Activity and Effective Substrate Reduction in Fabry Mice

Preliminary Safety and Efficacy Results from PRECIZN-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF 07055480/SB 525) Gene Therapy in Adults With Severe Hemophilia A

Our Pipeline

Translating groundbreaking science into tomorrow’s cures

Pioneering the future of genomic medicine

Read Elizabeth’s inspiring story of living with Fabry disease

Our Pipeline

Read Elizabeth’s
inspiring story
of living with
Fabry disease